Federated Hermes Inc. Reduces Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Federated Hermes Inc. lessened its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 11.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 396,568 shares of the biotechnology company's stock after selling 49,325 shares during the quarter. Federated Hermes Inc. owned about 0.71% of Repligen worth $71,303,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of RGEN. Invesco Ltd. increased its position in Repligen by 3.9% during the 1st quarter. Invesco Ltd. now owns 1,756,157 shares of the biotechnology company's stock worth $330,315,000 after buying an additional 65,550 shares during the period. State Street Corp increased its position in Repligen by 0.9% during the second quarter. State Street Corp now owns 1,651,310 shares of the biotechnology company's stock worth $233,594,000 after acquiring an additional 14,647 shares during the period. Artisan Partners Limited Partnership raised its stake in Repligen by 11.3% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company's stock worth $247,558,000 after purchasing an additional 157,807 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Repligen by 2.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company's stock valued at $222,075,000 after purchasing an additional 29,215 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Repligen by 13.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company's stock worth $190,117,000 after purchasing an additional 137,220 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on RGEN shares. KeyCorp lifted their price target on shares of Repligen from $210.00 to $220.00 and gave the company an "overweight" rating in a research report on Thursday, February 15th. Stifel Nicolaus lifted their price objective on Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $196.70.

Repligen Price Performance

Shares of RGEN traded up $0.08 during midday trading on Friday, hitting $157.14. The company's stock had a trading volume of 386,770 shares, compared to its average volume of 536,743. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. The company's fifty day simple moving average is $189.09 and its two-hundred day simple moving average is $173.09. The stock has a market capitalization of $8.77 billion, a price-to-earnings ratio of 218.25, a price-to-earnings-growth ratio of 5.27 and a beta of 1.02.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts' consensus estimates of $0.33. The company had revenue of $155.74 million for the quarter, compared to the consensus estimate of $155.38 million. Repligen had a net margin of 6.51% and a return on equity of 5.00%. The firm's quarterly revenue was down 16.6% compared to the same quarter last year. During the same period last year, the company posted $0.68 EPS. As a group, equities analysts expect that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insider Transactions at Repligen

In related news, COO James Bylund sold 4,373 shares of the firm's stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the sale, the chief operating officer now owns 14,135 shares of the company's stock, valued at approximately $2,799,860.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the company's stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the transaction, the chief executive officer now directly owns 185,249 shares in the company, valued at approximately $36,575,562.56. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO James Bylund sold 4,373 shares of Repligen stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total transaction of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares in the company, valued at approximately $2,799,860.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,597 shares of company stock worth $5,039,532. Corporate insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.